v3.26.1
Segment Reporting (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2026
USD ($)
segment
Mar. 31, 2025
USD ($)
Segment Reporting    
Number of operating segments | segment 2  
Number of reportable segments | segment 1  
Revenue $ 47,798 $ 41,040
Segment Reporting, Other Segment Item, Composition, Description Other segment items primarily includes professional services, facility allocations, dues and subscriptions, audit fees, insurance, legal fees, and travel expense.  
Adjusted EBITDA for reportable segments $ 3,571 1,026
Investment income 3,090 1,573
Unrealized loss on investments (1,062) 659
Foreign currency loss (800) 3,500
Stock-based compensation expense (2,395) (3,700)
Change in fair value of contingent consideration 15 (5,183)
Income taxes (108) (234)
Loss from continuing operations (9,432) (6,738)
Cost, employee related expenses 7,500 6,900
Cost, depreciation and amortization 2,200 2,000
Cost, stock-based compensation 400 600
Cost, rent 600 800
Engineering and development, employee related expenses 2,900 2,300
Engineering and development, depreciation and amortization 100 100
Engineering and development, stock based compensation 200 200
Life Sciences Services    
Segment Reporting    
Revenue 27,435 23,213
Cost of revenue 7,050 6,660
Employee related expenses 14,862 13,051
Engineering and development expense 202 983
Rent 1,851 1,803
Other segment items 4,044 3,445
Adjusted EBITDA for reportable segments (96) (2,484)
Life Sciences Products    
Segment Reporting    
Revenue 20,363 17,827
Cost of revenue 9,069 7,333
Employee related expenses 5,954 5,435
Engineering and development expense 513 412
Rent 178 187
Other segment items 1,476 1,100
Adjusted EBITDA for reportable segments 3,667 3,510
Operating segments    
Segment Reporting    
Revenue 48,770 41,435
Operating segments | Life Sciences Services    
Segment Reporting    
Revenue 27,913 23,458
Operating segments | Life Sciences Products    
Segment Reporting    
Revenue 20,857 17,977
Intersegment elimination    
Segment Reporting    
Revenue 972 395
Intersegment elimination | Life Sciences Services    
Segment Reporting    
Revenue 478 245
Intersegment elimination | Life Sciences Products    
Segment Reporting    
Revenue 494 150
Corporate non-segment    
Segment Reporting    
Corporate overhead costs (4,182) (3,845)
Depreciation and amortization expense (6,402) (6,134)
Acquisition and integration costs   (1)
Cost reduction initiatives   (216)
Investment income 3,090 1,573
Unrealized loss on investments (2,105) (193)
Foreign currency loss (454) (245)
Interest expense, net (432) (583)
Stock-based compensation expense (2,395) (3,064)
Change in fair value of contingent consideration (15) 5,178
Income taxes (108) (234)
Loss from continuing operations $ (9,432) $ (6,738)